1.Siegel, RL, Miller, KD & Jemal, A (2018) Cancer statistics, 2018. CA Cancer J Clin 68, 7–30.
2.Sullivan, R, Pramesh, CS & Booth, CM (2017) Cancer patients need better care, not just more technology. Nature 549, 325–328.
3.Siegel, R, Naishadham, D & Jemal, A (2012) Cancer statistics, 2012. CA Cancer J Clin 62, 10–29.
4.Hölzel, M, Bovier, A & Tüting, T (2013) Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat Rev Cancer 13, 365–376.
5.Le Tourneau, C, Delord, JP, Gonçalves, A et al. (2015) Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol 16, 1324–1334.
6.Del Paggio, JC, Sullivan, R, Schrag, D et al. (2017) Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks. Lancet Oncol 18, 887–894.
7.Davis, C, Naci, H, Gurpinar, E et al. (2017) Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009–13. Br Med J 359, j4530.
8.Muscaritoli, M, Lucia, S, Farcomeni, A et al. (2017) Prevalence of malnutrition in patients at first medical oncology visit: the PreMiO study. Oncotarget 8, 79884–79896.
9.Lu, Z, Yang, L, Yu, J et al. (2014) Change of body weight and macrophage inhibitory cytokine-1 during chemotherapy in advanced gastric cancer: what is their clinical significance? PLoS ONE 9, e88553.
10.Patel, JD, Pereira, JR, Chen, J et al. (2016) Relationship between efficacy outcomes and weight gain during treatment of advanced, non-squamous, non-small-cell lung cancer patients. Ann Oncol 27, 1612–1619.
11.Meyerhardt, JA, Kroenke, CH, Prado, CM et al. (2017) Association of weight change after colorectal cancer diagnosis and outcomes in the Kaiser Permanente Northern California population. Cancer Epidemiol Biomarkers Prev 26, 30–37.
12.Jouinot, A, Vazeille, C, Durand, JP et al. (2018) Resting energy expenditure in the risk assessment of anticancer treatments. Clin Nutr 37, 558–565.
13.Nasrah, R, Kanbalian, M, Van Der Borch, C et al. (2018) Defining the role of dietary intake in determining weight change in patients with cancer cachexia. Clin Nutr 37, 235–241.
14.Arends, J, Bachmann, P, Baracos, V et al. (2017) ESPEN guidelines on nutrition in cancer patients. Clin Nutr 36, 11–48.
15.Baracos, VE, Martin, L, Korc, M et al. (2018) Cancer-associated cachexia. Nat Rev Dis Primers 4, 17105.
16.Fearon, K, Strasser, F, Anker, SD et al. (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12, 489–495.
17.Cespedes Feliciano, EM, Lee, VS, Prado, CM et al. (2017) Muscle mass at the time of diagnosis of nonmetastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant FOLFOX: the C-SCANS study. Cancer 123, 4868–4877.
18.Lieffers, JR, Bathe, OF, Fassbender, K et al. (2012) Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery. Br J Cancer 107, 931–936.
19.Stene, GB, Helbostad, JL, Amundsen, T et al. (2015) Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer. Acta Oncol 54, 340–348.
20.Kimura, M, Naito, T, Kenmotsu, H et al. (2015) Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer. Support Care Cancer 23, 1699–1708.
21.Cespedes Feliciano, EM, Kroenke, CH, Bradshaw, PT et al. (2017) Postdiagnosis weight change and survival following a diagnosis of early-stage breast cancer. Cancer Epidemiol Biomarkers Prev 26, 44–50.
22.de van der Schueren, M, Laviano, A, Blanchard, H et al. (2018) Systematic review and meta-analysis of the evidence for oral nutritional intervention on nutritional and clinical outcomes during chemo(radio)therapy: current evidence and guidance for future trials. Ann Oncol 29, 1141–1153.
23.Lunney, JR, Lynn, J, Foley, DJ et al. (2003) Patterns of functional decline at the end of life. JAMA 289, 2387–2392.
24.Prado, CM, Sawyer, MB, Ghosh, S et al. (2013) Central tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable anabolic potential? Am J Clin Nutr 98, 1012–1019.
25.Cox, S, Powell, C, Carter, B et al. (2016) Role of nutritional status and intervention in oesophageal cancer treated with definitive chemoradiotherapy: outcomes from SCOPE1. Br J Cancer 115, 172–177.
26.Van Blarigan, EL, Fuchs, CS, Niedzwiecki, D et al. (2018) Association of survival with adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors after colon cancer diagnosis – The CALGB 89803/alliance trial. JAMA Oncol 4, 783–790.
27.Song, M, Zhang, X, Meyerhardt, JA et al. (2017) Marine ω-3 polyunsaturated fatty acid intake and survival after colorectal cancer diagnosis. Gut 66, 1790–1796.
28.Van Blarigan, EL, Fuchs, CS, Niedzwiecki, D et al. (2018) Marine ω-3 polyunsaturated fatty acid and fish intake after colon cancer diagnosis and survival: CALGB 89803 (alliance). Cancer Epidemiol Biomarkers Prev 27, 438–445.
29.Shirai, Y, Okugawa, Y, Hishida, A et al. (2017) Fish oil-enriched nutrition combined with systemic chemotherapy for gastrointestinal cancer patients with cancer cachexia. Sci Rep 7, 4826.
30.Nakao, M, Muramatsu, H, Kagawa, Y et al. (2017) Immunological status may predict response to nivolumab in non-small cell lung cancer without driver mutations. Anticancer Res 37, 3781–3786.
31.Flint, TR, Janowitz, T, Connell, CM et al. (2016) Tumor-induced IL-6 reprograms host metabolism to suppress anti-tumor immunity. Cell Metab 24, 672–684.
32.Haun, MW, Estel, S, Rücker, G et al. (2017) Early palliative care for adults with advanced cancer. Cochrane Database Syst Rev 6, CD011129.
33.Ferrell, BR, Temel, JS, Temin, S et al. (2017) Integration of palliative care into standard oncology care: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 35, 96–112.